TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06242808

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food resource coaching
Description: Patients will meet with a food resource coach who will explain basic coaching principles including how to respond to financial crises, how to access various food resources, and the importance of consistent utilization of food resources. After the coaching session, the food resource coach will help patients select medically tailored groceries from the free community food market inventory.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Free community food support
Description: Usual services include selecting up to 21 meals for each person in the household from Crossroads nutritious market once per month (e.g., approximately 100 pounds \[$250 United States dollars\] of food for a family of four)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Free community food support
Description: Usual services include selecting up to 21 meals for each person in the household from Crossroads nutritious market once per month (e.g., approximately 100 pounds \[$250 United States dollars\] of food for a family of four)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Free community food support
Description: Usual services include selecting up to 21 meals for each person in the household from Crossroads nutritious market once per month (e.g., approximately 100 pounds \[$250 United States dollars\] of food for a family of four)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medically tailored groceries
Description: A pantry staff member helps patients select medically tailored groceries (MTG) from the free community food market inventory by prepopulating MTG in their pantry cart.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medically tailored groceries
Description: A pantry staff member helps patients select medically tailored groceries (MTG) from the free community food market inventory by prepopulating MTG in their pantry cart.
Study: NCT05956457

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Health Coaching Program
Description: Digital health intervention consisting of weekly calls from a Health Advisor to a participant, accompanied by delivery of evidence-based content across health and wellness domains (e.g. nutrition, exercise, physical, emotional and financial health) up to 4 times weekly via text, email or mobile application.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: A wrist-worn activity tracker allowing for the capture of physical activity, including but not limited to step-count and minutes of activity, to be captured daily.
Study: NCT06520826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vadadustat
Description: A synthetic, orally bioavailable, small molecule being developed as an inhibitor of hypoxia-inducible factor prolyl-hydroxylases for the treatment of anemia associated with chronic kidney disease. Intervention to be administered to maintain hemoglobin within a target range of 10-11 g/dL.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythropoiesis Stimulating Agent
Description: Standard of care erythropoiesis stimulating agent will be administered to maintain hemoglobin within a target range of 10-11 g/dL.
Study: NCT06466278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icosapent ethyl
Description: 2dd2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2dd2
Study: NCT06370845

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Inhalation - Natural Odour
Description: Inhalation of 50 uL of a natural odour via nasal septum mini-inhaler.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Inhalation - Placebo
Description: Inhalation of 50 uL of Placebo via nasal septum mini-inhaler.
Study: NCT05044507

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BQ 2.0
Description: frequency and intensity parameters will be set to zero so that no stimulation is delivered

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: BQ 2.0
Description: frequency and intensity parameters will be set to zero so that no stimulation is delivered

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BQ 2.0
Description: The BQ 2.0 is a medical device that produces and delivers non-invasive, extremely low intensity and frequency (1-100 Hz.; up to 1 G), frequency tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: BQ 2.0
Description: The BQ 2.0 is a medical device that produces and delivers non-invasive, extremely low intensity and frequency (1-100 Hz.; up to 1 G), frequency tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery
Study: NCT04684823

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patch Cap
Description: A prescription container cap to track the dispensing of an oral dose of medication with an associated app which tracks the adherence to medication regimen.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patch App
Description: A mobile app that is used with Patch Cap to track adherence to medication regimen
Study: NCT05348941

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TECADRIOL
Description: Food supplement containing an association of D-chiro-inositol and alpha-lactalbumin
Study: NCT03514329

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bronchoscopic Thermal Vapor Ablation
Description: Vapor (steam) is infused into the targeted region for 8 seconds at a precisely controlled flow rate and power.
Study: NCT06220305

Intervention type: DIAGNOSTIC_TEST
Intervention: DNA methylation joint AI imaging
Description: DNA were extracted from patients'plasma ,then the DNA was bisulfite converted and tested by DNA methylation assay.The results were combined with AI images to differentiate between benign and malignant lung nodules.
Study: NCT05467293

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.3% YP-P10 Ophthalmic Solution
Description: Drug: YP-P10 Ophthalmic Solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% YP-P10 Ophthalmic Solution
Description: Drug: YP-P10 Ophthalmic Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: YP-P10 Placebo Ophthalmic Solution (vehicle)
Description: Placebo YP-P10 Placebo Ophthalmic Solution (vehicle)
Study: NCT05171790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1706 injection
Description: 5 mg/kg, IV, Q3w
Study: NCT06404619

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education program
Description: The message emphasizes the importance of quality of life and positive psychology. The concept of quality of life is described as multidimensional, also the message highlights the steps to change one's lifestyle, including self-reflection, habit modification, and commitment to a comprehensive lifestyle change include importance of physical activity, management of stress, quality and quantity of sleep and specific recommendations are provided regarding drinking water, organizing meals, and adopting a healthy balanced diet with attention to portion sizes. The message also discussed fitness foods that aid digestion and promote a healthy body. The message introduced the Healthy Eating Plate.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education program
Description: The message emphasizes the importance of quality of life and positive psychology. The concept of quality of life is described as multidimensional, also the message highlights the steps to change one's lifestyle, including self-reflection, habit modification, and commitment to a comprehensive lifestyle change include importance of physical activity, management of stress, quality and quantity of sleep and specific recommendations are provided regarding drinking water, organizing meals, and adopting a healthy balanced diet with attention to portion sizes. The message also discussed fitness foods that aid digestion and promote a healthy body. The message introduced the Healthy Eating Plate.
Study: NCT05828316

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resilience-based intervention
Description: resilience-based intervention is a curriculum that offers a careful selection of evidence-based exercises to build coping skills and promote thriving. The resilience-based intervention philosophy is that there are many routes to achieving greater resiliency. Each participants choose from a menu of exercises in the areas of goal-setting, emotional skills, social connection, health, meaning, and self-talk. The ability to choose exercises that fit their specific goals, interests, and schedules is important, because the most effective strategies are the ones that people actually do, which tend to be the ones that are most enjoyable and personally relevant. No single practice is going to work for everyone regardless of its proven benefits. resilience-based intervention makes improving well-being accessible, manageable and fun, by introducing a variety of bite-sized, exercises that participants can experiment with and find what works for them.
Study: NCT05413915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asciminib
Description: Tyrosine kinase inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imatinib
Description: Tyrosine kinase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Tyrosine kinase inhibitor
Study: NCT04396249

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tVNS
Description: One electrode tip is used as their common terminal, and the other two electrode tips are respectively connected to the skin surfaces of the auricle and the external auditory meatus. Each subject will have 10 active tVNS sessions.The active tVNS group will be stimulated with a 2 mA current for 30 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tVNS
Description: Each subject will have 10 sham tVNS sessions.The sham tVNS group will be stimulated with a 2 mA current for 30 minutes. Except for the stimulation site, other parameters are the same as active group.
Study: NCT06179225

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HMD AR
Description: Older adults will wear head mounted display to engage in collaborative augmented reality activities: sharing a meal, playing board games, and decorating home.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 2-D AV
Description: Older adults will use 2-D AV to engage with family members at a distance.
Study: NCT06137274

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy
Description: All patients will be treated with intensity-modulated radiotherapy (IMRT) plans.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Guidance
Description: All patients will undergo combined CT and/or MR simulation and will be treated with a sequential-boost technique.
Study: NCT04955249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Patients in this group receive dexmedetomidine-supplemented patient-controlled analgesia for up to 3 days after surgery. The formula is a mixture of dexmedetomidine (1 microgram/ml) and sufentanil (1 microgram/ml), diluted with normal saline to 200 ml. The analgesic pump is programmed to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout interval of 8 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in this group receive routine patient-controlled intravenous analgesia for up to 3 days after surgery. The formula is a mixture of placebo and sufentanil (1 microgram/ml), diluted with normal saline to 200 ml. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout interval of 8 minutes.
Study: NCT05353205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flumatinib mesylate tablets (400mg)
Description: Flumatinib 400mg +Placebo for flumatinib are administered orally daily. Patients are randomized to flumatinib 400mg QD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flumatinib mesylate tablets (600mg)
Description: Flumatinib 600mg is administered orally daily. Patients are randomized to flumatinib 600mg QD.
Study: NCT06116747

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Support for fathers of preterm infants
Study: NCT06161207

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Indocyanine Green Tracer Using in 3D plus Ultra High Resolution Laparoscopic Gastrectomy with Lymph Node Dissection
Description: Indocyanine green tracer is used with 3D plus ultra high resolution laparoscopic gastrectomy with lymph node Dissection for gastric cancer

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Indocyanine Green Tracer Using in 3D plus Ultra High Resolution Laparoscopic Gastrectomy with Lymph Node Dissection
Description: Indocyanine green tracer is used with 3D plus ultra high resolution laparoscopic gastrectomy with lymph node Dissection for gastric cancer

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Indocyanine Green Tracer Using in 3D plus Ultra High Resolution Laparoscopic Gastrectomy with Lymph Node Dissection
Description: Indocyanine green tracer is used with 3D plus ultra high resolution laparoscopic gastrectomy with lymph node Dissection for gastric cancer
Study: NCT06359262

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hope@School
Description: A digital platform aimed at promoting student mental health in schools

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Regular student health care in schools
Study: NCT05686863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: Remazolam for sedation in children undergoing bidirectional endoscopy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esketamine
Description: Esketamine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Esketamine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: remifentanil
Description: remifentanil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remifentanil
Description: remifentanil
Study: NCT03612466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 153Sm-DOTMP
Description: For Levels 1- 3, the Day 1 dosages will be the same (0.5 millicurie (mCi)/kg 153Sm-DOTMP) for all levels but the Day 8 dosages will be 0.5, 1.0 and 3.0 mCi/kg respectively. For Levels 4, 5 \& 6, the Day 1 dosages will be the same (0.5 mCi/kg 153Sm-DOTMP) for all levels but the Day 8 dosages will be 3, 6, then 10 mCi/kg 153Sm-DOTMP respectively.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy.
Description: The amount of radiation will be determined based on how much radiation was delivered to each tumor by the 153Sm-DOTMP, and will be targeted to 70 Gray (Gy)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Carbonate
Description: Calcium carbonate will be given to participants as prophylaxis against hypocalcemia..

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mozobil
Description: Participants who require stem cell collection will be given Mozobil to help mobilize hematopoietic stem cells into the circulation for collection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neupogen Injectable Product
Description: Participants who require stem cell collection will be given Neupogen to help mobilize hematopoietic stem cells into the circulation for collection.
Study: NCT05874102

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sidelying
Description: Position sidelying then Upright

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sidelying
Description: Position sidelying then Upright

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Upright
Description: Position upright then sidelying

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Upright
Description: Position upright then sidelying
Study: NCT05418439

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Drink Poppi Soda
Description: Drink Poppi Vinager Soda
Study: NCT05554640

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acuvue® Oasys MAX 1-Day
Description: TEST Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acuvue® Oasys MAX 1-Day
Description: TEST Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dailies Total 1
Description: CONTROL Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dailies Total 1
Description: CONTROL Lens
Study: NCT05361564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brigatinib
Description: After 7-day lead-in 90mg/day, brigatinib 180mg/day from 4 to 10weeks(optimal duration: 6 weeks)
Study: NCT05917652

Intervention type: BEHAVIORAL
Intervention: Tool kit
Description: The study team will develop and design key elements of the implementation intervention (toolkit) among a small group of burn and non-burn clinician stakeholders (4-6 total). The study team will use in-person interviews with stakeholders and a semi-structured interview guide to elicit feedback and assess face and content validity of the toolkit elements prior to deployment across the study hospitals. For those who consent to participation, the study team will conduct virtual teleconference interviews in-person using a secure videoconferencing platform while the person is not working, at a time convenient for them. Interviews will last between 45 and 60 minutes. The study team anticipates conducting 4-6 interviews to finalize toolkit elements prior to implementation.

Intervention type: BEHAVIORAL
Intervention: Tool kit
Description: The study team will develop and design key elements of the implementation intervention (toolkit) among a small group of burn and non-burn clinician stakeholders (4-6 total). The study team will use in-person interviews with stakeholders and a semi-structured interview guide to elicit feedback and assess face and content validity of the toolkit elements prior to deployment across the study hospitals. For those who consent to participation, the study team will conduct virtual teleconference interviews in-person using a secure videoconferencing platform while the person is not working, at a time convenient for them. Interviews will last between 45 and 60 minutes. The study team anticipates conducting 4-6 interviews to finalize toolkit elements prior to implementation.
Study: NCT04773743

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Remotely delivered yoga intervention
Study: NCT04848389

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin Adhesive procedure
Description: The scar is closed in 2 planes. The subcutaneous plane is closed with an absorbable 3/0 vicryl-type thread, the cutaneous plane is closed by applying skin adhesive. A drying time of 25 seconds is necessary to obtain a satisfactory seal.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard suture procedure
Description: The scar is closed in 2 planes. The subcutaneous plane is closed with an absorbable thread of the 3/0 Vicryl-type, the cutaneous plane is closed with the same thread with an subcutaneous stitch.
Study: NCT05049577

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Analgesia/Nociception Index (ANI)
Description: V1 and V5 electrocardiographic positions as per the manufacturer's recommendations. The ANI was continuously recorded and displayed with a frequency of 1 Hz. ANI scores measured immediately before propofol administration, half-dose administration (1mg/kg), and full-dose administration (2mg/kg)of propofol.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Analgesia/Nociception Index (ANI)
Description: V1 and V5 electrocardiographic positions as per the manufacturer's recommendations. The ANI was continuously recorded and displayed with a frequency of 1 Hz. ANI scores measured immediately before propofol administration, half-dose administration (1mg/kg), and full-dose administration (2mg/kg)of propofol.
Study: NCT05324670

Intervention type: OTHER
Group type: OTHER
Intervention: Didactic model for suicidal behavior in the framework of impulsivity and ideations
Description: It will be in the form of lectures (Educational approach). Content will be developed one day before the commencement of the session. The Knowledge provided in the form of written material with proper explanation shall not exceed 30 minutes and a Focused group Discussion will be held at the end of each month.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Didactic model for suicidal behavior in the framework of impulsivity and ideations
Description: It will be in the form of lectures (Educational approach). Content will be developed one day before the commencement of the session. The Knowledge provided in the form of written material with proper explanation shall not exceed 30 minutes and a Focused group Discussion will be held at the end of each month.
Study: NCT05422690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction Chemotherapy Triplet Therapy
Description: Gemcitabine 1000 mg/m2, Cisplatin 25 mg/m2 infused on both day 1 and day 8 of a 21-day cycle. Durvalumab 1500 mg will be given on day 1 of each cycle.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Concurrent Y-90 treatment
Description: Patients will undergo a Y-90 treatment planning consultation by the treating interventional radiologist during cycle 1. One or two cycles (depending on tumor size) of cisplatin, 25 mg/m2 and gemcitabine 300 mg/m2 given on day 1 and day 8 in combination with Yttrium-90 (Y-90) microspheres which will be given on day 3-7 or day 10-21 at the discretion of the interventional radiologist, separated in time by at least 2 days from a chemo infusion during that cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Consolidation Doublet Therapy:
Description: Gemcitabine 1000 mg/m2 and Cisplatin 25 mg/m2 given on days 1 and 8 of a 21-day cycle with durvalumab 1500 mg given on day 1 of each cycle for 3-5 additional cycles. For the cycle directly after Y-90, gemcitabine will be kept at a dose of 300 mg/m2 to minimize risk of toxicity.
Study: NCT06318338

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Program
Description: Study participants will be provided a HTC or Pico VR head-mounted device (HTC Flow, HTC Focus or Pico Neo Pro) which will be fitted for comfort. Patients will remain seated for the entirety of the VR program. The program generally takes about ten minutes to complete but may last up to 11 minutes. The program displays a relaxing environmental setting with narration based in mindfulness meditation principles. Subjects will be prompted to practice breathing exercises designed to relax and reduce anxiety.